• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib.

作者信息

De Stefano Ludovico, Bobbio-Pallavicini Francesca, Montecucco Carlomaurizio, Bugatti Serena

机构信息

Division of Rheumatology, IRCCS Policlinico San Matteo Foundation.

Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

出版信息

Rheumatology (Oxford). 2022 Mar 2;61(3):e64-e66. doi: 10.1093/rheumatology/keab771.

DOI:10.1093/rheumatology/keab771
PMID:34647989
Abstract
摘要

相似文献

1
Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib.巴瑞替尼成功治疗度普利尤单抗诱发的附着点炎和难治性特应性皮炎。
Rheumatology (Oxford). 2022 Mar 2;61(3):e64-e66. doi: 10.1093/rheumatology/keab771.
2
Comprehensive real-world comparisons between baricitinib and dupilumab treatments for moderate to severe atopic dermatitis.巴瑞替尼与度普利尤单抗治疗中度至重度特应性皮炎的全面真实世界比较。
J Allergy Clin Immunol Pract. 2024 Jul;12(7):1924-1927.e1. doi: 10.1016/j.jaip.2024.04.008. Epub 2024 Apr 10.
3
Acute spondyloarthritis developing during successful treatment with dupilumab for severe atopic dermatitis.在使用度普利尤单抗成功治疗重度特应性皮炎期间发生的急性脊柱关节炎。
Clin Exp Dermatol. 2022 Mar;47(3):592-593. doi: 10.1111/ced.14984. Epub 2021 Dec 9.
4
Switching from baricitinib to dupilumab as an advanced-line treatment in pediatric patients with atopic dermatitis: a retrospective cohort study.在患有特应性皮炎的儿科患者中，从巴瑞替尼转换为度普利尤单抗作为晚期治疗：一项回顾性队列研究。
Int J Dermatol. 2024 Jul;63(7):e130-e132. doi: 10.1111/ijd.17198. Epub 2024 May 15.
5
The effect of baricitinib add-on therapy in atopic dermatitis patients treated with dupilumab.
Dermatol Ther. 2022 Jul;35(7):e15525. doi: 10.1111/dth.15525. Epub 2022 Apr 25.
6
Dupilumab-associated facial and neck dermatitis successfully treated with baricitinib.巴瑞替尼成功治疗度普利尤单抗相关的面部和颈部皮炎。
J Dtsch Dermatol Ges. 2024 May;22(5):704-705. doi: 10.1111/ddg.15355. Epub 2024 Mar 12.
7
Re: Johansson E, Giovannitti M, Mezzetti M, et al. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. J Med Econ. 2023;26(1):1155-1166.
J Med Econ. 2024 Jan-Dec;27(1):800-802. doi: 10.1080/13696998.2024.2357978. Epub 2024 Jun 10.
8
Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children.病例报告：度普利尤单抗和巴瑞替尼序贯疗法治疗儿童伴有特应性皮炎的重症斑秃。
Front Immunol. 2024 Jun 6;15:1395288. doi: 10.3389/fimmu.2024.1395288. eCollection 2024.
9
Treatment of moderate-to-severe atopic dermatitis with baricitinib: Results from an interim analysis of the TREATgermany registry.巴瑞替尼治疗中重度特应性皮炎：来自德国TREAT注册研究的中期分析结果
J Eur Acad Dermatol Venereol. 2024 Oct;38(10):e887-e891. doi: 10.1111/jdv.19979. Epub 2024 Mar 28.
10
A case of palmoplantar pustulosis with atopic dermatitis: Baricitinib is a safe and effective treatment.
Indian J Dermatol Venereol Leprol. 2024 Sep-Oct;90(5):668-670. doi: 10.25259/IJDVL_884_2023.

引用本文的文献

1
Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Biologics and JAK inhibitors.韩国特应性皮炎治疗的基于共识的指南（第二部分）：生物制剂和JAK抑制剂
Ann Dermatol. 2025 Aug;37(4):216-227. doi: 10.5021/ad.24.154.
2
Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020-2023.巴瑞替尼治疗特应性皮炎和斑秃的真实世界证据：2020 - 2023年系统文献综述
Dermatol Ther (Heidelb). 2025 May 16. doi: 10.1007/s13555-025-01425-y.
3
Differential immunological profiles in seronegative versus seropositive rheumatoid arthritis: Th17/Treg dysregulation and IL-4.
血清阴性与血清阳性类风湿关节炎的免疫差异特征：Th17/Treg 失调与 IL-4。
Front Immunol. 2024 Sep 3;15:1447213. doi: 10.3389/fimmu.2024.1447213. eCollection 2024.
4
Successful treatment of the dupilumab-induced psoriatic dermatitis/arthritis and atopic dermatitis with a JAK inhibitor: A case report and literature review.使用JAK抑制剂成功治疗度普利尤单抗诱导的银屑病性皮炎/关节炎和特应性皮炎：一例病例报告及文献综述
J Allergy Clin Immunol Glob. 2024 Aug 5;3(4):100323. doi: 10.1016/j.jacig.2024.100323. eCollection 2024 Nov.